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A novel calix[4]pyrrole derivative 
as a potential anticancer agent that 
forms genotoxic adducts with DNA
Marta Geretto1, Marco Ponassi2, Martina Casale3, Alessandra Pulliero1, Grazia Cafeo3, 
Ferdinando Malagreca3, Aldo Profumo2, Enrica Balza2, Rakhmetkazhi Bersimbaev4, 
Franz Heinrich Kohnke3, Camillo Rosano2 & Alberto Izzotti1,2
meso-(p-acetamidophenyl)-calix[4]pyrrole 3 was found to exhibit remarkable cytotoxicity towards A549 
cancer cells. A comparative study including the isomer of 3 meso-(m-acetamidophenyl)-calix[4]pyrrole 
5, as well as molecules containing ‘fragments’ of these structures, demonstrated that both the calix[4]
pyrrole and the acetamidophenyl units are essential for high cytotoxicity. Although calix[4]pyrroles 
and other anion-complexing ionophores have recently been reported to induce apoptosis by perturbing 
cellular chloride concentrations, in our study an alternative mechanism has emerged, as proven 
by the isolation of covalent DNA adducts revealed by the 32P postlabelling technique. Preliminary 
pharmacokinetic studies indicate that 3 is able to cross the Blood-Brain-Barrier, therefore being a 
potential drug that could kill primary and brain metastatic cancer cells simultaneously.
Calix[n]pyrroles are macrocyclic compounds made up of pyrrole units linked at their 2,5-positions by quaternary 
carbon atoms1. meso-Octamethyl-calix[4]pyrrole 1 (Fig. 1) has been known for over a century2, but interest in 
this compound (and its congeners) rapidly developed only following the discovery of its ability to form complexes 
with anions3 and neutral molecules4 that can accept hydrogen bonds from the pyrrole NH units. Since these 
seminal papers, a vast number of calixpyrrole derivatives have been synthesised and investigated as selective lig-
ands for different anions1,5, for sensing applications6, in the assembly of novel materials7,8 and devices9,10. When 
developing our early work on heterocyclophanes11 and calixarenes12 that can bind biologically relevant species, 
we reported the ability of meso-p-aminophenylcalix[4]pyrrole 2 to form a cytotoxic trans-Pt(II) complex in which 
the calix unit appears to assist the delivery of the toxic metal to DNA via the preliminary binding of the phosphate 
residues13. In this work, we propose a mechanism by which ‘free’ non-Pt(II) coordinated calixpyrrole 2 is released 
within the cell when the metal leaves the aminophenyl coordination site of 2 to form new bonds with nitrogen 
atoms of the nucleobases. Since tests conducted with ‘free’ 2 did not reveal any significant cytotoxicity when this 
was used at concentrations analogous to that of its Pt(II) complex, it was evident that 2 acted merely as a vector 
capable of delivering the toxic metal to DNA. To the best of our knowledge, this is the first report on the use of a 
calixpyrrole derivative for potential biomedical applications as a drug-delivery system.
The crucial role of ion channels for cell function has been widely recognised14, and targeting the ion transport 
mechanism is known to provide a means of affecting cell viability15. Hence, as lipophilic anion-complexing agents 
capable of transporting anions across lipid membranes, calixpyrroles can be considered potentially cytotoxic. 
They can be viewed as the anion-binding counterparts of the well-known cation-binding ionophoric antibiotics 
valinomycin16 and nonactin17. Studies conducted by J. L. Sessler, P. A. Gale, I. Shin and collaborators have demon-
strated that some pyridine diamide strapped calixpyroles can affect chloride transport coupled to sodium cation 
transport in cells18. This leads to increased chloride and sodium concentrations within the cell and ultimately to 
cell death by apoptosis. This work was later extended to other chloride complexing agents beside calixpyrroles19. 
It was found that a delicate balance has to be achieved between binding strength and lipophilic character for a 
chloride-binding receptor to achieve effective transport and exhibit cytotoxic properties19. In these studies18, 
calixpyrrole 1 was shown (Fig. 1) not to exhibit significant cytotoxicity, therefore we were not surprised that 
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calixpyrole 2 was also found to be non cytotoxic13. However, it is reasonable to assume chloride not to be the only 
anion that can be targeted by using ionophores to achieve a cytotoxic effect. For this reason, we recently reported 
the synthesised calixpyrrole-based receptors containing two or three calixpyrrole units and evaluated their abil-
ity to bind bis-carboxylates that are relevant to cancer physiology20,21, planning to investigate their biological 
activities in future studies. Moreover, we previously reported that the meso-octamethyl-calix[4]pyrrole 1 acts as 
antagonist of the G-protein coupled receptor 30 (GPR30) in different model systems, such as breast tumour cells 
and cancer-associated fibroblasts22. The latter work clearly indicated that calixpyrroles have the potential to elicit 
a biological response by a mechanism that is not linked to their properties as ionophores, but as ligands of the 
estrogenic receptor GPR30. We therefore selected compounds 3 and 5 shown in Fig. 1 to expand our study on the 
biological activity of calix[4]pyrrole derivatives because they can be viewed as substructures of the bis- and tris- 
aromatic amide-linked calixpyrroles reported by us previously20, and they clearly comprise structure 1.
Here we report on the cytotoxic properties of 3 and 5 against several different cancer cell lines and a limited 
pharmacokinetic (organotropism) evaluation of compound 3 in mice. The pharmacokinetic study was limited to 
3 because this was found to be the most active of the tested compounds against the highly aggressive A549 lung 
cancer cells.
Figure 1. Structural formulae for meso-octamethyl-calix[4]pyrrole 1 and for the related compounds tested in 
this study.
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We were not expecting strong evidence for the formation of covalent DNA adducts to emerge during this 
study. This unexpected result suggests that specific calix[4]pyrrole derivatives could be used as novel genotoxic 
drugs inducing apoptosis by a mechanism that is not linked to their activity as ionophores.
Results
A timing-course experiment performed using 3 or 5 against the A549 lung cancer cell line (Fig. 2) showed that 
upon treatment with either compound, a high mortality rate (measured by the crystal violet method) occurred 
at 24 h, while at 3, 6 and 12 h no significant cytotoxic effect could be detected. Cell mortality after 48 hours was 
100%.
To elucidate which structural features present in 3 and 5 were necessary for the observed activity, we virtually 
fragmented these molecules to test their structural components as separate units. This led us to select, synthe-
sise and test the small library of compounds (2, 4, 6, 7, 8) shown in Fig. 1. Although we had already tested 2 in 
previous studies, this compound was included in the screening for validation purposes. Calixpyrrole 6 (Fig. 1) 
was included to assess whether the presence of two p-acetanilide units would produce enhanced cytotoxicity 
compared to 3 (which contains only one such unit). Calixpyrrole 6 was obtained by acetylation (acetyl chloride, 
K2CO3 in DCM) of the p-aminophenyl analogue which has been reported previously23. Dipyrromethanes 7 and 
8 were prepared by N-acetylation (acetyl chloride, K2CO3 in DCM) of the previously reported 4-aminophenyl13 
and 3-aminophenyl23 analogues.
After preliminary tests on 3 and 5 using the crystal violet method, we tested the cytotoxic properties of the 
different calixpyrroles 2, 3, 4, 5, 6, and of compounds 7 and 8 using the MTT method. Table 1 summarizes the 
concentrations needed to induce a 50% decrease of cellular viability at the indicated times for the tested com-
pounds against lung, breast, ovary and astrocytoma cancer cells in vitro.
MTT assays performed on the differentiated H727 lung cancer cell line showed compounds 3 and 5 to be 
effective in decreasing cell viability at the lowest dose (less than 5 μM) with no further significant differences 
in their behaviour detected compared with the other doses tested (Fig. 3A). Calixpyrrole derivatives were only 
slightly more effective in decreasing viability of poorly differentiated A549 cells than those of more differentiated 
Figure 2. Effects of compounds 3 and 5 on cell viability (crystal violet). Adenocarcinoma A549 lung cancer 
cell line treated with 5 μM of calix 3 (blue line) and 5 (orange line) shows a time-dependent decreased viability 
compared to control (100% viability) ***p < 0.001; **p < 0.01; *p < 0.05.
Entry Cell Types
Compounds (see Fig. 1) Evaluation 
time in 










d < 5 50 < d < 100 d < 5 50 < d < 100 d > 100 d > 100 d > 100 24.0





10 < d < 20 50 < d < 100 10 < d < 20 d > 100 N.T. N.T. N.T. 48.0
5 SKOV3 OVARIAN 20 < d < 30 50 < d < 100 5 < d < 10 50 < d < 100 N.T. d > 100 d > 100 48.0
6 U87MG GLIOMA ASTROCYTOMA 50 < d < 100 N.T. 50 < d < 100 N.T. N.T. N.T. N.T. 24.0
Table 1. Estimated concentration (d, μM) of compounds necessary to induce a 50% decrease in cellular 
viability. N.T.: not tested.
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H727 cells (Fig. 3A,B, and Table 1 entries 1 and 2 respectively). MTT tests were also performed on U87MG 
(Astrocytoma), MCF-7, MDA-MB-231 (Breast) and SKOV-3 (Ovarian) cancer cell lines. When used on U87MG 
astrocytoma cells (Fig. 3F, Table 1 entry 6), compounds 3 and 5 were almost non-effective. Against breast can-
cer cells MCF-7 and MDA-MB-231 (Fig. 3C,D, and Table 1 entries 3 and 4 respectively), 3 and 5 showed their 
highest efficacy after 48 h at a dose between 10μM and 30 μM, 5 being slightly more effective than 3. This activity 
seems independent of the estrogenic state of the cell line tested (MCF7 is ER + while MDA-MB-231 is triple 
Figure 3. MTT assays on cancer cell lines treated with compounds 3, 5 and 6 at different concentrations  
(5, 10, 20, 30, 50 μM), for 24 h (Panels A,B and F,G) or 48 h (Panels C,D). ***p < 0.001; **p < 0.01; *p < 0.05. 
Control corresponds to 100%. Panel A: Lung cancer poorly aggressive H727 cells; Panel B: Lung cancer highly 
aggressive, A549 cell line; Panel C: Breast cancer ER positive, MCF-7 cell line; Panel D: Breast cancer triple 
negative, MDA-MB-231 cell line; Panel E: Ovarian cancer, SKOV3 cell line; Panel F: Glioma astrocytoma, 
U87MG cell line; Panel G: A549 cells treated with compound 6.
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negative) and it is very limited at doses between 10 μM and 5 μM. However, 3 and 5 were notably more effective 
against SKOV3 ovarian cancer cell lines (after 48 h of exposure, Fig. 3E, Table 1 entry 5) than against MCF7 and 
MDA-MB-231. Compound 5 in particular seems to be more efficient than 3 towards this tumour cell line, with an 
estimated viability of 50% on exposure to a 10 μM dose of compound.
A cellular viability test was then performed exposing A549 lung cancer cell lines to 6, since this cell type 
appeared the most affected by 3. After 24 h, we detected no significant effect even at the higher dose (Fig. 3G, 
Table 1 entry 2). The dipyrromethane derivatives 7 and 8 were inactive against A549 cancer cells (Table 1 entry 
2), these data confirming that both the calix[4]pyrrole moiety and one meso acetanilide substituent are necessary 
components for the cytotoxic properties of 3 and 5.
To shed light on the pharmacodynamics of calix derivatives, we examined the influence of the S12 liver frac-
tion24 on drug efficacy. S12 remarkably decreases the effectiveness of calix 3 in killing lung cancer cells (light blue 
column) as compared to the cytotoxic activity displayed in the absence of S12 (Fig. 4 dark blue column). Thus, 3 
undergoes a phase II detoxification reaction in the liver resulting in drug catabolism, detoxification and decreased 
activity. Accordingly, these molecules, in vivo, cannot be administered by the oral route but only by the parenteral 
route using subcutaneous injection. Intravenous administration should be avoided due to the high lipophilicity 
of these compounds that could lead to embolism.
The efficacy of 3 against A549 lung cancer cells was compared with that of Taxol. Cells were exposed to 
increasing concentrations of 3 and Taxol (10, 30, 50 μM, both dispensed with the same solvent, see method sec-
tion) for 12 h because this is the time-span normally employed to test highly cytotoxic drugs used in chemother-
apy such as Taxol. In fact, after longer times the residual viability was too low to allow significant comparisons. At 
concentrations higher than 20 μM (see the intersection between the two plots in Fig. 5), compound 3 appears to 
be better at killing cancer cells than Taxol.
Following the evaluation of the cytotoxic properties of compounds 3 and 5 against the above indicated cancer 
cell lines, we explored the mechanism of action by which cell death occurred. This work was limited to A549 
Figure 4. MTT assay on A549 lung cancer cell line using 5μM of the indicated compound in the absence (dark 
colour) and in the presence (light colour) of the S12 liver fraction (12 h exposure). ***p < 0.001; **p < 0.01; 
*p < 0.05. K indicates the control.
Figure 5. MTT assay on A549 lung cancer cell line treated for 12 h with 3 (blue line) or Taxol (violet line). 
Control corresponds to 100%, p < 0.001.
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cells, as this cell line was found to be the most affected by these calixpyrrole derivatives. Flow cytometric analysis 
indicated apoptosis to be the main mechanism. Indeed, A549 cells treated with compound 3 showed 38.80% of 
total apoptosis (9.05% early apoptosis and 29.75% late apoptosis) compared to 9.30% of necrosis. In the same cell 
line, compound 5 determined 23.45% of total apoptosis (10.25% early apoptosis and 13.20% late apoptosis) while 
necrosis accounted for 4.75% (Fig. 6).
COMET assay (Fig. 7) shows DNA fragmentation in cells treated with compound 3, which was able to induce 
massive DNA damage at each concentration tested. However, a higher concentration was required to achieve a 
similar effect with 5. Compounds 2 and 4 were significantly less effective than 3 and 5 at all concentrations tested.
The ability of calixpyrrole derivatives 3 and 5 to bind DNA was determined by analysing the formation of 
lipophilic DNA adducts in treated cells by the 32P postlabelling technique25 (Fig. 8). The DNA of treated cells 
was depolymerised into single nucleotides, adducts were extracted by washing with water-saturated butanol 
and labelled by 32P using AT-gamma-32P as donors and T4 nucleotide kinase. Adducts were resolved by 
multi-directional thin layer chromatography on polyethylenimine-coated cellulose sheets using sodium phos-
phate and urea buffers and identified by electronic autoradiography as previously reported25–27.
The comparative analysis between controls and calixpyrrole-treated cells revealed the formation of specific 
DNA adducts only in treated cells, as detected by thin layer chromatography and autoradiography (highlighted by 
dashed line circles in Fig. 8). These are characterized by the low chromatographic mobility that can be predicted 
Figure 6. Apoptosis profile (Muse™ Annexin V & Dead Cell Assay) for A549 cells treated with 3 or 5 (5 μM), 
or DMSO alone (the same amount used to dissolve 3 or 5: 0.1% of DMSO) and untreated cells (K). Profiles were 
determined 24 h after treatment in all cases. Each plot has 4 quadrant markers, reflecting the different cellular 
states: the upper left quadrant contains dead cells (necrosis), the upper right has late apoptotic/dead cells (cells 
that are positive both for Annexin V and for cell death marker 7-AAD, 7-Aminoactinomycin D), the lower left 
contains live cells and the lower right early apoptotic cells (cells that are positive only for Annexin V).
www.nature.com/scientificreports/
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for lipophilic/bulky covalent adducts of 3 or 5 and/or of their metabolites to DNA. These adducts were enriched 
by butanol extraction of the enzymatically digested DNA, thus being identifiable as highly lipophilic adducts, 
a characteristic that would arise from the presence of the calixpyrrole component. The adduct amounts were 
4.2 ± 0.51 and 4.5 ± 0.28 adducts/108 normal nucleotides for compounds 3 and 5, respectively (mean ± SD of 3 
independent replicated experiments).
MicroRNA Expression. Microarray analysis indicates that treatment with 3 remarkably modified miRNA 
expression (Fig. 9). Scatter plots highlight that multiple miRNAs changed their expression more than 2-fold in 
treated cells (vertical axis) as compared to sham-control (horizontal axis), as shown by the many dots located 
outside the diagonal variation interval indicated by the green lines (Fig. 9). Volcano plot analysis, considering 
two selection criteria, (i.e. higher than 2-fold variation and statistically significant variation P < 0.05) identified 
38 miRNAs whose expression was altered by compound 3. These miRNAs are involved in a variety of biological 
Figure 7. COMET assays on A549 cell line. The assay evaluates DNA fragmentation by quantifying % DNA 
in tails formed from A549 cell nuclei after treatment with the different calixpyrroles (5–50 μM dose, 24 h in all 
cases), followed by alkali treatment and single-cell electrophoresis. Microphotographs show the appearance 
of DNA distribution in ‘comet tails’ following a 5 μM dose treatment: (A) sham-treated control; (B–E) for 5, 
3, 4, and 2 respectively. Panel F: % DNA in tail in A549 cells when the test was conducted using the indicated 
concentrations of compounds 2–5.
www.nature.com/scientificreports/
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Figure 8. Detection of DNA adduct in A549 cells: sham-treated (panel A); treated with 3 (panel B), or with 
5 (panel C). Adducts were labelled by 32P and purified by multi-directional thin layer chromatography whose 
origin is located in the bottom left corners (OR). Adducts (white dashed line circles) are identified as radioactive 
(black) spots by electronic autoradiography performed by phosphoro-imager. D2, direction of second 
chromatographic elution (urea buffer pH 3.5); D3, direction of third chromatography elution (urea buffer 
pH = 8.5); D1 and D4 elutions (not reported) with washing buffers (sodium phosphate). D1 elution direction was 
opposite to D2; D4 elution was the same as D3. The black areas on the right correspond to the final edge of the 
chromatogram.
Figure 9. microRNA expression as evaluated by microarray analysis in A549 cells either sham-treated or 
treated with 3. Panel A: hybridised microarray showing the fluorescent miRNA captured onto immobilised 
probes; the call-response rate (i.e. the number of fluorescent spots) is high (>90%) indicating a good quality 
analysis. Panel B: scatter plot analysis comparing the level of expression of each one of the 1,350 analyzed 
miRNA (dots) in sham (horizontal axis) versus 3-treated cells (vertical axis). Dots falling outside the 1.5-fold 
variation interval (diagonal green lines) are either upregulated (upper left area) or downregulated (lower right 
area) by 3. Dot colours indicate the level of miRNA expression (blue low, yellow intermediate, red high). Panel 
C: Volcano plot analysis of miRNA modulated by 3 as compared to control. miRNAs are reported as dots 
located according to fold-variation difference (horizontal axis, > 1.5-fold indicated by the two vertical green 
lines) and statistical significance of difference calculated by ANOVA (vertical axis, P value < 0.05 log values 
indicated by the green horizontal line). miRNAs located outside the green lines (i.e. > 1.5-fold and P < 0.05, red 
dots) are significantly modulated by 3.
www.nature.com/scientificreports/
9SCIENtIFIC RePoRts |  (2018) 8:11075  | DOI:10.1038/s41598-018-29314-9
functions, as detailed in S.I. Table 1. These findings explain at epigenetic level the activation of apoptotic and 
necrotic pathways consequent to the high degree of DNA damage induced by 3 in lung cancer A549 cells.
In vivo evaluation of pharmacokinetic and organ distribution. A preliminary analysis of in vivo 
toxicity was conducted using only compound 3 in A/J mice. Since 3 is particularly hydrophobic, a mixture con-
taining 10% DMSO in olive oil was selected as a suitable solvent, after testing its solubility in various means, for 
administration to the animal. Five mice received solvent alone (sham control) and five mice solvent plus com-
pound 3. The amount of solvent administered was identical for sham and drug-treated mice. Increasing amounts 
of 3 (vide infra) could be administered using this solvent without exceeding the previously reported28,29 safe limit 
for DMSO of 1 ml/Kg, in fact no adverse effects were observed for either sham or treated mice. Computational 
simulations30 indicated for compound 3 a rodent oral lethal dose (LD50) of 920 mg/kg. In order to experimen-
tally determine an LD50 in mice, we injected subcutaneously a first dose of 5 mg/Kg which was then increased 
5-fold up to 50-fold, with no visible effects on the animals, in line with the computational simulation. Finally, we 
changed administration from subcutaneous to intraperitoneal, again without detecting any apparent effects. After 
five days the animals were sacrificed, and the distribution of the compound within the various compartments was 
determined by HPLC/MS analysis. Whole cell homogenate was used for the analysis after cell debris removal. 
Under these conditions, cell homogenates include the cellular cytoplasmic fraction plus the nuclear fraction.
Dorsal subcutaneous tissue, spleen, omentum, heart, liver, brain, lung and kidney were removed and homog-
enised. Concentrations of 3 in tissues/organs were determined by evaluating the area of the extracted ion cur-
rent at m/z 546.31, corresponding to the compound under analysis [M-H]−. The highest value was found in the 
omentum (1,237,999), a high value was observed at the injection site (532,875) and in the spleen (196,233). Lower 
concentrations were found in the kidneys (120,117), lungs (32,514) and heart (29,443). Low levels were found in 
the liver (11,293) and brain (7,735), showing that 3 is able to pass the blood brain barrier (BBB). Thus the amount 
of 3 found in the brain accounts for only 0.3%, but this value corresponds to ca. 2% if referred to the sum of the 
amounts found in target organs alone (S.I. Fig. 1).
Discussion
Structures 3 and 5 were identified as interesting candidates to expand our knowledge on the biological activity of 
calixpyrroles with a view to further biological studies on more complex bis- and tris-calixpyrrole systems20,21. We 
were expecting to be able to rationalize any biological activity observed for these compounds either in terms of 
their properties as ionophores or as modulators of growth on cells expressing the GPR30 receptor22. After expo-
sure to 3 and 5, cancer cell lines die by apoptosis after 24 to 48 h, as demonstrated by time course and Annexin 
V tests. While this type of cell death would be compatible with the disruption of cell homeostasis due to 3 and 5 
acting as chloride ionophores, the isolation of DNA covalent adducts and the numerous and considerable changes 
in miRNA expression for A549 cells exposed to 3 provide evidence for genetic damage to be the likely primary 
cause of the observed cytotoxicity. This action is rather selective: 3 and 5 showed an EC50 < 5μM when tested on 
A549 and H727 cell lines but they were less effective against SKOV3 cell lines and were almost ineffective against 
U87MG Glioma astrocytoma cells.
The small library of compounds selected for testing enables us to conclude that both the calixpyrrole and 
one meso-N-acetamido-substituent are necessary for the observed cytotoxicity. Although we cannot exclude that 
some other meso-substituents could produce cytotoxic molecules, we can conclude that some (e.g. meso-4 or 
meso-3-aminophenyl, present in 2 and 4 where the acetyl residue is missing) do lead to inactive compounds (at 
least against the cell lines tested in this study).
A change in the position (meso-4 or meso-3-aminoacetyl) unit (see 3 versus 5) does not cause dramatic 
changes in cytotoxicity, but the replacement of the calixpyrrole with a ‘half calix moiety’ produces the inactive 
compounds 7 and 8. The lack of activity found for compound 6 indicates that the presence of additional acet-
anilide units on the calixpyrrole frame does not produce a more active compound, although we cannot exclude 
that other isomers of 6 might be active. The relative chloride affinities of 3 and 6 in acetonitrile were evaluated by 
means of 1H NMR spectroscopy, and differences were marginal31. This result is compatible with chloride trans-
port not being the key to explain the different activities of 3 and 6. The comparative evaluation of the biological 
activities of the compounds in Fig. 1 enabled us to conclude that the cytotoxicity of 3 and of 5 are both due to 
the combined role of three structural elements: i) a single acetanilide unit at ii) a meso-position of iii) a complete 
calix[4]pyrrole structure.
The ability of calixpyrrole derivatives to bind phosphate via multiple hydrogen-bonds (including when this 
is part of a nucleotide) has been documented previously for a number of analogues of 3 or 532,33. However, the 
observed DNA adducts were covalent, which could be ascribed to the reactivity of the acetanilide portion. Indeed, 
aromatic amines and several of their derivatives are known to form covalent bonds with DNA nucleobases34,35. 
This hypothesis is also consistent with the previously reported ability of acetanilide derivatives to form covalent 
DNA adducts, as in the study by Rogers on paracetamol36, where the 32P postlabelling technique was also used. 
The crucial role of the calixpyrrole unit for the cytotoxicity of 3 and 5 is proven by the lack of activity of com-
pounds 7 and 8. Therefore, the calixpyrrole component must somehow contribute to the reactivity between DNA 
and the acetanilide component (presumably as a metabolically activated derivative) of 3 and 5. We can hypothe-
sise that this could take place via three mechanisms.
One mechanism assumes that the initial non-covalent binding of the calix moiety with phosphate brings the 
acetanilide unit of the calix into proximity of the nucleobase(s) with a spatial arrangement similar to the one we 
have proposed previously for the delivery to DNA of cis-Pt(II) complex with calixpyrrole 213.
A second hypothesis is that some nucleobases might act as ‘guests’ that could be ‘recognised’ by the calix-
pyrroles 3 and 5. In a preliminary evaluation of this hypothesis, 1:1 solutions of the DNA nucleobases and 3 
in DMSO/acetonitrile were examined by negative ESI-MS. Indeed, adenine and cytosine produced a 1:1 
www.nature.com/scientificreports/
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supramolecular complex (see S.I. Figs 3 and 4). If this process were occurring, one would expect the formation 
of the covalent adducts to take place when the double helix unwinds and the strands separate for replication. In 
this phase the nucleobases would be ‘free’ to be complexed by the calixpyrrole, this event being followed by an 
‘intra-complex’ alkylation of the nucleobase by the acetanilide component.
A third mechanism could be based on the potential for 3 and 5 to act as minor groove binders. To test this 
hypothesis we performed in silico docking experiments in which the calixpyrrole unit of 3 was constrained in the 
cone conformation typically observed in anionic complexes with phosphates and the meso-p-acetanilide unit 
was pointing either equatorially or perpendicularly with respect to the macroring mean-plane. The modelling 
indicated the potential of 3 to act as a minor groove binder that places the amide very close to an adenine N3 
atom (3.7 Å, see S.I. Fig. 2). Similar results were obtained by constraining the calixpyrrole unit in a 1,3-alternate 
conformation. This type of interaction is reminiscent of the ability of other polypyrrole-imidazole polyamides37 
and polypyrrole amides38 to act as DNA minor groove binders39. These have been shown to enhance the cytotoxic 
potency of DNA alkylating agents when covalently linked to the pyrrole oligomer37, this effect being consistent 
with the intercalator playing a role in the active delivery of the alkylating moiety to DNA. Although the structural 
similarity between polypyrrole-imidazole polyamides or polypyrrole amides and calixpyrroles 3 and 5 is limited, 
the in silico experiments suggest that the calixpyrrole unit may be involved in the active delivery of the (presum-
ably metabolically activated) alkylating acetanilide component present in their structure via preliminary minor 
groove binding. Therefore the potential for 3 to be a minor groove binder, as indicated by the molecular docking 
simulation, combined with the known mechanism by which aromatic amides form DNA adducts34–36, suggests 
that in 3 (and also in 5) two portions of the molecule act synergically to produce the genotoxic damage that leads 
to cell death.
We also hypothesise that the lack of activity of 6 might be due to the enhanced steric hindrance of the two 
p-acetanilide units that could prevent its insertion (or that of an ‘activated’ metabolite) into the DNA minor 
groove. If metabolic activation is a key step, 6 might lack activity due to it not being a substrate for the activation 
process.
Finally, one cannot exclude that a combination of these three mechanisms could be operating: the initial 
step could be phosphate binding, followed by insertion in the minor groove, with nucleobase binding and 
intra-complex alkylation as the last step. Although the precise mechanism by which 3 and 5 form adducts with 
DNA has still to be uncovered, a survey of the literature provides good support for the hypotheses described 
above.
Calixpyrrole 3 not only caused DNA damage (formation of adducts and fragmentation), but also induced epi-
genetic alterations (miRNA). Taken together these effects provide further information on the pro-apoptotic effect 
of 3. MiRNA expressions are highly sensitive to exposure to genotoxic agents40 by a process involving the binding 
of electrophilic metabolites to miRNA precursors in cytoplasm and the alteration induced in the nucleophilic cat-
alytic pocket of DICER41. The functions of altered miRNA (Table S1I) shed light on the mechanisms triggered by 
3 to kill cancer cells. Indeed, the majority of modulated miRNAs are involved in cell cycle blockage and apoptosis 
activation. Two modulated miRNAs (miR-34, miR-660) are directly linked to the P53 pathway, this indicating 
that apoptosis is triggered as a consequence of DNA damage. General anti-oncogenic activity is envisaged for 
many modulated miRNAs including oncogene suppression, TGF inhibition, blockage of EMT transition, cell 
migration invasion and metastatisation. Overall, these data provide evidence of the specific anti-cancer activity 
deployed at epigenetic level by calixpyrrole 3.
The pharmacokinetic study was limited to 3 because this was found to be the most active of the tested com-
pounds against the highly aggressive A549 lung cancer cells. Our interest in this was motivated by the fact that 
lung cancer represents the most frequently occurring form of this disease and it is also the most common cause of 
death from cancer worldwide. The prognosis for lung cancer is poor42; in most countries there is a 5-year survival 
rate of 10%. One of the reasons for such a low survival rate is the ability of lung cancer to give rise to metastases 
affecting mainly the brain, as well as other organs43. Primary and secondary brain tumours are particularly diffi-
cult to manage due to the BBB hampering drug penetration. The calix[4]pyrrole derivatives selected in this study 
are highly lipophilic, this being an important prerequisite to pass the BBB44.
The method used for the bio-distribution studies gave the ratios of compound 3 in the different tissues. These 
proportions were determined by using equal weights of the different tissues that were analysed by the same 
method, therefore the ion currents measured for the MS peak of 3 in the different tissues could be compared 
directly. Compound 3 is highly lipophilic, and it is not surprising that it accumulates in the omentum, while the 
high concentration at the injection point is also explained by its low solubility in aqueous medium. The propor-
tion of 3 reaching the target organs was only 18% of the total quantity found in the various tissues taken together. 
This 18% was distributed in the organs as shown in Fig. S1. The omentum may act as a natural reservoir for the 
administered calixpyrrole 3. In this preliminary study we did not investigate how the biodistribution changes over 
time or upon the loss of fatty tissue by an animal affected by a developing cancer. As regards the ‘mobile’ fraction 
of 3, significant amounts reach the lungs (8%) and the brain (2%). This is particularly interesting because of the 
highly effective activity of 3 against the A549 lung cancer cells. The ability to cross the BBB is of great importance 
since brain metastases are common evolutions of lung cancers that are extremely difficult to treat43. Therefore, the 
observed biodistribution data for 3 are of great interest. The in vivo study also indicated no apparent short-term 
toxic effects even at very high dosages (up to 250 mg/Kg).
In conclusion, the results described herein indicate that 3 and 5 can be considered lead structures for the 
development of novel potentially selective anticancer drugs that can be tolerated in vivo45.
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Materials and Methods
General procedure. Solvents were dried using molecular sieves (4 Å) or by following standard procedures46. 
Pyrrole was distilled before use. All other chemicals were standard reagent grade and were used without further 
purification. All air and/or moisture-sensitive reactions were conducted under an inert atmosphere. Thin-layer 
chromatography was carried out on Merck SiO2 60F254 plastic plates. Compounds were visualised with vanillin 
or by examination under UV light. Column chromatography was conducted using silica gel (Aldrich, 230–400 
mesh, 60 Å). 1H and 13C NMR spectra were recorded on a Varian 500 spectrometer at 500 and 125 MHz, respec-
tively, with the residual proton resonances of the solvent (CD2Cl2) used as references. NMR solvent was used as 
supplied in sealed ampoules and care was taken to minimize exposure to moisture. MS spectra were recorded on 
Agilent 6210 TOF mass spectrometer (Agilent Technologies, Palo Alto, CA, USA) equipped with an electrospray 
ion source operating in negative polarity for compounds 2, 5 and 6, and on a triple quadrupole WATERS TQMS 
spectrometer operating in positive polarity for 7 and 8.
Before being used for the biological tests, compounds 2–8 were vacuum-dried to remove traces of residual 
ethyl acetate (EtOAc) from the chromatographic purifications.
meso-(4-aminophenyl)-meso-hepta(methyl)calix[4]pyrrole 2. This compound was prepared as described by us 
previously13.
meso-(4-acetamidophenyl)-meso-hepta(methyl)calix[4]pyrrole 3. A solution of acetyl chloride (31.1 mg, 
0.4 mmol) in dry DCM (2 mL) was gradually added to a stirred suspension of 2 (200 mg, 0.4 mmol) and excess 
K2CO3 (55.3 mg, 0.4 mmol) in DCM (20 mL), at room temperature, in Ar atmosphere. The reaction was moni-
tored by TLC (SiO2, DCM) until complete disappearance of the starting material (30 min.). The reaction mixture 
was extracted with water (1 × 15 mL) and with a saturated solution of NaHCO3 (1 × 15 mL). The organic phase 
was dried (MgSO4) and concentrated under reduced pressure. The crude was subjected to column chromatog-
raphy (SiO2, DCM, DCM/EtOAc, 9:1) to give 2 (108 mg. 49%, m.p. < 250 °C from EtOAc, dec.) as a white solid 
which appeared pure by TLC, 1H and 13C NMR analyses and ESI-MS analyses. 1H NMR (500 MHz, CD2Cl2) δ 1.48 
(s, 3 H, CH3), 1.50 (s, 6 H, CH3), 1.52 (s, 3 H, CH3), 1.56 (s, 6 H, CH3), 1.85 (s, 3 H, CH3), 2.11 (s, 3 H, COCH3), 
5.65 (m, 2 H, pyrrole β-CH), 5.87 (m, 4 H, pyrrole β-CH), 5.91 (m, 2 H, pyrrole β-CH), 6.91 (AB system, 2 H, 
Ar-CH), 7.13 (sb, 2 H, pyrrole-NH), 7.23 (sb, 1 H, NHCO), 7.27 (sb, 2 H, pyrrole-NH), 7.34 (AB system, 2 H, 
Ar-CH); 13C NMR (125 MHz, CD2Cl2) δ 24.6, 27.6, 27.8, 28.2, 29.9, 30.1 (CH3), 35.3, 35.3, 44.5 (Cq), 103.0, 
103.0, 103.3, 106.1 (pyrrole-CH), 119.2, 128.1 (Ar-CH), 136.7, 137.7, 138.6, 138.8, 139.2, 144.0 (Cq), 168.4 (CO). 
Calculated for C35H41N5O 547.33111; found (ESI-MS) [M-H]− 546.3106, the calculated and observed isotopic 
patterns were in good agreement.
meso-(3-aminophenyl)-meso-hepta(methyl)calix[4]pyrrole 4. This compound was prepared as described by us 
previously20.
meso-(3-acetamidophenyl)-meso-hepta(methyl)calix[4]pyrrole 5. This compound was prepared by N-acetylation 
of compound 4 as described for 3. (including the same quantities): (46%, 100 mg, m.p. < 250 °C from EtOAc, 
dec.); 1H NMR (500 MHz, CD2Cl2) δ 1.49 (s, 9 H, CH3), 1.52 (s, 3 H, CH3), 1.56 (s, 6 H, CH3), 1.87 (s, 3 H, CH3), 
2.07 (s, 3 H, COCH3), 5.72 (m, 2 H, pyrrole β-CH), 5.88 (m, 4 H, pyrrole β-CH), 5.92 (m, 2 H, pyrrole β-CH), 6.72 
(d, 1 H, Ar-CH), 7.04 (s, 1 H, Ar-CH), 7.19 (t, 1 H, Ar-CH), 7.23 (sb, 1 H, NHCO), 7.34 (sb, 2 H, pyrrole-NH), 
7.35 (d, 1 H, Ar-CH), 7.48 (sb, 2 H, pyrrole-NH); 13C NMR (125 MHz, CD2Cl2) δ 24.5, 27.9, 27.9, 28.3, 29.9, 29.9 
(CH3), 35.3, 35.4, 44.9 (Cq), 103.0, 103.0, 103.1, 105.8 (pyrrole-CH), 118.8, 120.1, 123.9, 128.5 (Ar-CH), 136.5, 
137.6, 138.7, 138.9, 139.3, 149.3 (Cq), 168.6 (CO). Calculated for C35H41N5O 547.33111; found (ESI-MS) [M-H]− 
546.3111, the calculated and experimental isotopic patterns were in good agreement.
(10α,20α)-10,20-bis(4-acemidophenyl) 5,5,10,15,15,20-hexamethy-calix[4]pyrrole 6. This compound was 
obtained by bis N-acetylation of the previously reported23 (10α,20α)-10,20-bis(4-acemidophenyl)5,5,10,15,15,
20-hexamethy-calix[4]pyrrole as described for 3, doubling the amounts of acetylchloride and K2CO3. 6: (47% 
125 mg, m.p. < 250 °C from EtOAc, dec); 1H NMR (500 MHz, CD2Cl2) δ 1.51 (s, 6 H, CH3), 1.62 (s, 6 H, CH3), 
1.86 (s, 6 H, CH3), 2.10 (s, 6 H, COCH3), 5.63 (m, 4 H, pyrrole β-CH), 5.92 (m, 4 H, pyrrole β-CH), 6.89 (AB sys-
tem, 4 H, Ar-CH), 7.21 (sb, 2 H, NHCO), 7.30 (sb, 4 H, pyrrole-NH), 7.34 (AB system, 4 H, Ar-CH); 13 C NMR 
(125 MHz, CD2Cl2) δ 24.4 (COCH3), 26.9, 27.4, 30.0 (CH3), 34.9, 44.2 (Cq), 103.1, 105.8 (pyrrole-CH), 118.8, 
127.8 (Ar-CH), 136.4, 138.4, 143.8 (Cq), 168.1 (CO). Calculated for C42H46N6O2 666.36822; found (ESI-MS) 
[M-H]− 665.3571.
5-Methyl-5-(4-acetamidophenyl)dipyrromethane 7. This compound was prepared by N-acylation of the previ-
ously reported13 5-Methyl-5-(4-aminophenyl)dipyrromethane, as described for 3.
7: (80%); 1H NMR (500 MHz, CD2Cl2) δ 2.01 (s, 3 H, CH3), 2.08 (s, 3 H, COCH3), 5.94 (m, 2 H, pyrrole β-CH), 
6.11 (m, 2 H, pyrrole β-CH), 6.65 (m, 2 H, pyrrole α-CH), 7.02 (AB system, 2 H, Ar-CH), 7.34 (AB system, 2 H, 
Ar-CH), 7.44 (sb, 1 H, NHCO), 8.06 (sb, 2 H, pyrrole-NH); 13C NMR (125 MHz, CD2Cl2) δ 24.4, 28.9 (CH3), 44.5 
(Cq), 106.3, 108.1, 117.4 (pyrrole-CH), 120.2, 128.8 (Ar-CH), 136.7, 137.7, 143.8 (Cq), 168.7 (CO). Calculated 
for C18H19N3O 293,15281; found (ESI-MS) [M + H]+ 294.22, the calculated and experimental isotopic patterns 
were in good agreement.
5-Methyl-5-(3-acetamidophenyl)dipyrromethane 8. This compound was prepared by N-acylation of 5-Methyl-
5-(3-aminophenyl)dipyrromethane20 as described for 3.
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8: (80%); 1H NMR (500 MHz, CD3CN) δ 1.95 (s, 3 H, CH3), 1.98 (s, 3 H, COCH3), 5.80 (m, 2 H, pyrrole β-CH), 
6.00 (m, 2 H, pyrrole β-CH), 6.64 (m, 2 H, pyrrole α-CH), 6.74 (d, 1 H, Ar-CH), 7.15 (s, 1 H, Ar-CH), 7.19 (t, 1 H, 
Ar-CH), 7.50 (d, 1 H, Ar-CH), 8.21 (sb, 1 H, NHCO), 8.69 (sb, 2 H, pyrrole-NH); 13C NMR (125 MHz, CD3CN) 
δ 23.9, 28.6 (CH3), 45.4 (Cq), 106.6, 107.9, 117.7 (pyrrole-CH), 118.0, 119.4, 123.3, 128.9 (Ar-CH), 138.2, 139.6, 
149.6 (Cq), 169.2 (CO). Calculated for C18H19N3O 293,15281; found (ESI-MS) [M + H]+ 294.12, the calculated 
and experimental isotopic patterns were in good agreement.
Cell culture. Human lung non-small cell carcinoma H727 and SKOV-3 ovary cancer cell lines were purchased 
from ATCC (Manassas, VA) and cultured respectively in RPMI (Pan-Biotech, Aidenbach, Germany) and DMEM 
(Sigma-Aldrich, Milan, Italy), both supplemented with 10% foetal calf serum (Euroclone, Milan, Italy), 2 mM 
L-glutamine (Euroclone, Milan, Italy) and 1% Penicillin-Streptomycin (Euroclone, Milan, Italy) at 37 °C in a 5% 
CO2 incubator. A549 human lung adenocarcinoma, U87MG glioblastoma, MCF7 (ER + ) and MDA-MB-231 
(ER-triple negative) human breast cancer cell lines were purchased from the BBCF (Biological Bank and Cell 
Factory, IRCCS Policlinico San Martino, Genoa, Italy). They were cultured in DMEM (Sigma-Aldrich, Milan, 
Italy), supplemented with 10% foetal calf serum (Euroclone, Milan, Italy), 2 mM L-glutamine (Euroclone, Milan, 
Italy) and 1% Penicillin-Streptomycin (Euroclone, Milan, Italy) at 37 °C in a 5% CO2 incubator.
Time-course experiment. A time-course experiment was performed by treating the A549 cell line with 
the lowest dose (5 μM) of compounds 3 and 5. The treatment was blocked after 3, 6, 12 and 24 hours. The cells 
were then fixed with Formalin, coloured with crystal violet and the results were read on a microplate photometer 
(Multiskan FC, Thermo Scientific) at 570 nm.
Pharmacokinetic studies with liver metabolic fraction (S12). The following working solutions were 
prepared:
 (a) 10 μM containing 3 or 5 with S12: a solution of 3 or 5 in DMSO (5 mM, 1μL) was diluted 1:500 with the fol-
lowing mixture: deionised water (33.2% v/v), phosphate-buffered saline (50% v/v, PBS, Euroclone, Milan, 
Italy), nicotinamide adenine dinucleotide phosphate (4% v/v, NADP, Sigma-Aldrich, Milan, Italy), glucose 
6-phosphate (0.5% v/v, G6P, Sigma-Aldrich, Milan, Italy), MgCl2 (2% v/v, BDH, VWR International, Mi-
lan, Italy) and S12 (10.3% v/v);
 (b) 10 mM containing 3 or 5 without S12: a solution of 3 or 5 in DMSO (5 mM, 1μL) was diluted 1:500 with 
the following mixture: deionised water (43.5% v/v), phosphate-buffered saline (50% v/v, PBS, Euroclone, 
Milan, Italy), nicotinamide adenine dinucleotide phosphate (4% v/v, NADP, Sigma-Aldrich, Milan, Italy), 
glucose 6-phosphate (0.5% v/v, G6P, Sigma-Aldrich, Milan, Italy), MgCl2 (2% v/v, BDH, VWR Internation-
al, Milan, Italy),
 (c) Sham test solution with S12: DMSO (1 μL) was diluted 1:500 as indicated for the solutions of 3 or 5 with 
S12;
 (d) Sham test solution without S12: DMSO (1 μL) was diluted 1:500 as indicated for the solutions of 3 or 5 
without S12.
A549 cell line was seeded in 96-microwell flat-bottom plates at a density of 6 × 103 cells per well in 100 μL of 
culture medium DMEM (Sigma-Aldrich, Milan, Italy). The next day, cells were treated with 100 μL of the working 
solutions, obtaining a 5 μM concentration for tests with 3 or 5 and identical content of DMSO (0.1%) in all cases, 
including sham tests. The solutions were incubated at 37 °C for 30 min. Both native functional S12 fraction and 
heat-inactivated (60 °C for 1 h) S12 were tested. Treatment time was 12 h, followed by the MTT test as described 
below.
Cell viability assays. To evaluate cell viability in response to chemical compound treatments, we performed 
MTT assays on lung, glioma-astrocytoma, breast and ovarian cancer cell lines. For this purpose a 5 mM stock 
solution of each compound was prepared in neat DMSO (Sigma-Aldrich, Milan, Italy) and this was then diluted 
with foetal bovine serum (Biosigma, Cona, Venice, Italy) in the following proportions: 1:50, 3:250, 1:250 and 
1:500. Working solutions having the following concentrations of compound and DMSO were thereby obtained: 
(100 μM, 2% DMSO), (60 μM, 1,2% DMSO), (20 μM, 0.4% DMSO), (10 μM, 0.2%). Adding 100 μL of the above 
working solutions to 100 μL of cell culture (as described below) resulted in a further 1:2 dilution and produced 
the concentrations 50 μM, 30 μM, 10 μM, and 5 μM (indicated in the viability plots of Fig. 3), containing 1%, 0.6%, 
0.2% and 0.1% DMSO respectively. Sham tests were conducted using identical concentrations of DMSO solvent 
alone.
Cells were seeded in 100 μl of medium at a concentration per well to reach ca. 80% of confluence in the 
untreated wells at the end of the assays. The next day, 100 μL of culture medium containing different concentra-
tions (10 μΜ–100 μΜ) of the tested compounds was added to cells. The cells were further incubated for 24 h. On 
the third day, 20 μl of MTT stock solution (2 mg/ml in PBS) was added for an additional 4 h of incubation. At the 
end of this incubation time, the precipitated formazan was dissolved in 100 μL of DMSO. After 20 min in the dark, 
the results were read on a microplate photometer (Multiskan FC, Thermo Scientific, Waltham, Massachusetts) 
at 570 nm and normalised with respect to the corresponding sham test (results are expressed as percentage of 
the control samples). Each test was repeated three times in eight replicates and means and standard deviations 
calculated.
Annexin-V apoptosis assay. A549 cells, seeded at a density of 2 × 105 cells per well in 1 mL of culture 
medium DMEM (Sigma-Aldrich, Milan, Italy), were treated with compounds 3 and 5 at a concentration of 5 μM 
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for 24 h. Muse™ Annexin V & Dead Cell Assay was then performed. Cells were dissociated from each well to 
obtain single-cell suspensions and 100 μL of these suspensions was added to each tube together with 100 μL of the 
Muse™ Annexin V & Dead Cell Reagent (BD Biosciences Pharmingen 2350 Qume Drive San Jose, California, 
USA). The samples were mixed thoroughly by vortexing at a medium speed for 3 to 5 seconds and were then 
stained at room temperature in the dark for 20 min, before being analysed by flow cytometry (FACS Canto II 
cytometer, Becton Dickinson BD).
Comet assay. A549 cells were seeded in 6-well flat-bottom plates at a density of 2 × 104 cells per well in 1 mL 
of culture medium DMEM (Sigma-Aldrich, Milan, Italy) and treated with compounds 2–5 (5 μM). After 24 h, 
the cells were dissociated using trypsin (Euroclone), centrifuged at 1000 rpm x 5 min, suspended in 1% (w/v) 
low-melting-point agarose at a concentration of 1 × 104 cells/mL and applied to the surface of a microscope slide 
to form a microgel and allowed to set at 4 °C for 5 min. The slides were submerged overnight at 4 °C in cell lysis 
buffer solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris-HCl, pH 10) to which 1% Triton X-100 and 10% DMSO 
were added before use. An alkaline solution (0.3 M NaOH, 1 mM EDTA, pH 13) was prepared to perform DNA 
unwinding and electrophoresis at 300 mA and 25 V. After the neutralisation step, the slides were dehydrated with 
absolute ethanol. Analyses of samples were carried out on slides stained with ethidium bromide (2 μg/ml in H2O) 
using a fluorescence microscope at 200X magnification (Leica Microsystems, Mannheim, Germany) equipped 
with a digital camera. Images of at least 100 randomly selected nuclei were acquired and analysed using an auto-
mated imaging system CASP or Comet Assay (SoftwareProject, http://www.casp.sourceforge.net). DNA damage 
(alkali–labile sites and both double- and single-stranded DNA breaks) was quantified in terms of % tail DNA. All 
results are expressed as mean ± SD. The statistical significance was evaluated by ANOVA and Student’s t test47.
DNA adducts. A549 cells, grown in two 75 cm2 flasks, were treated for 24 h, one with compound 3 and the 
other with 5, both at the concentration of 5 μM. A third flask with A549 cells was used as control. The cells were 
then detached and DNA was extracted using the GenElute Mammalian Genomic DNA Miniprep Kit following 
the manufacturer’s instructions (Sigma-Aldrich, Milan, Italy). Aliquots of 6 μg DNA were assayed, after butanol 
extraction, to evaluate the presence of adducts by 32P postlabelling27,48.
MicroRNA expression. A549 total RNA was purified from the supernatant using a commercially available 
kit (miRNeasy, Qiagen, Valencia, CA, USA) by adding 100% ethanol and centrifuging at 8000 × g. The spin col-
umns were washed twice, and the trapped RNA was eluted using ultrapure water (80 μl). The amounts and purity 
of extracted RNA were evaluated by fiber optic spectrophotometer (Nanodrop ND-1000, Thermo Scientific, 
Wilmington, DE, USA). To evaluate the expression of miRNAs, the 7th generation miRCURY LNA™ microRNA 
Array (Exiqon, Vedbaek, Denmark) was used, which contains 3100 capture probes covering human, mouse, 
and rat. This microarray analyses the expression of 1928 human miRNAs. The total RNA from each sample was 
labelled using Label IT® miRNA Labelling Kits, version 2 (Mirus Bio, Madison, WI, USA) following the stand-
ard protocol. Total RNA (500 ng) was mixed with 10 μl labelling buffer, 4 μl Label IT reagent (containing Cy3 or 
Cy5 fluorescent tracers), and water 86 μl. The samples were incubated at 37 °C for 1 h and the reaction stopped 
by adding 10 μl Stop Reagent. Differently labelled samples (with Cy3 and Cy5, respectively) were purified by 
column chromatography in 25 μl elution buffer. Hybridisation solution (2 × 25 μl, EXIQON) was then added and 
mixed thoroughly, and the resulting mixture denatured at 65 °C for 3 min. The labelled mix was transferred to the 
microarray and covered with coverslips. The hybridisation was performed in GlassArray Hybridization Cassettes 
(Invitrogen Ltd, Paisley, UK) in a water bath at 37 °C for 16 h and then a wash sequence performed. The array was 
dried by centrifugation and scanned by a laser scanner (ScanArray, PerkinElmer, Waltham, MA, USA) to record 
fluorescent signals produced by each spotted probe effectively hybridised with the corresponding miRNA49.
In vivo study. Based on the observed efficacy in vitro, compound 3 was chosen for preliminary in vivo stud-
ies. The main challenge was to find a non-toxic solvent for mice in which this compound could be dissolved. We 
therefore performed solubility tests using various solvents, including olive oil, propylene glycol, aqueous solution 
of sodium chloride 2 M and dimethyl sulfoxide (DMSO). Suspensions of compound 3 were obtained using each 
of these solvents alone, except for DMSO, and also heating the solutions. Finally, we achieved solubility using 
10% DMSO in olive oil. A/J mice were used for the in vivo studies. The Web Server PROTOX30 predicted an oral 
LD50 of 920 mg/kg in rodents for 3 and this was used to determine the amount of compound to be administered. 
Since we decided to inject the solution of 3 subcutaneously, we started with a low dose (5 mg/Kg), subsequently 
increasing the amount 5- and 50-fold and we also changed administration from subcutaneous to intraperitoneal.
All treatments were performed in line with the ethical guidelines for animal experiments of the European 
Community Directive 2010/63/UO 22/09/2010 and the Guide for the care and use of laboratory animals 8th 
edition, The US National Academic Press 2010. The experimental protocol was approved by the Institute of Cell 
Biology and Biotechnology, L.N. Gumilyov Eurasian National University, Astana, Kazakhstan.
Biodistribution of 3. To measure the distribution of compound 3 in different organs of mice, we performed 
a preliminary analysis using HPLC-MS. Mice were subcutaneously injected with 250 mg/Kg of compound 3 
and five days later organs (lung, brain, spleen, omentum, kidney, liver, heart) were harvested as well as dorsal 
subcutaneous tissue from the injection site. Identical amounts (87 mg) were used for HPLC/MS. The protocol50 
requires that each sample is suspended in water (10 μl/mg) and homogenised for 3 min at 30 s−1 using TissueLyser 
(Qiagen, Hilden, Germany). Ethanol was then added to each sample (1:2 homogenate:ethanol), vortexed, centri-
fuged (13,200 rpm, 10 min) and the supernatant was collected. This step was repeated using equal volumes of eth-
anol and homogenate. The supernatants were stored at −80 °C. The amount of 3 was determined by HPLC-ESI/
TOF-MS, operating in negative ion mode, using an Agilent 1200 series chromatographic system, equipped with 
G1379B degasser, G1376A capillary pump, and G1377A autosampler. Each cryopreserved (1900 μL) sample was 
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centrifuged (14,000 rpm, 15 min) and vacuum-dried in SpeedVac overnight. Pellets were resuspended in acetoni-
trile (100 μL), sonicated for 5 min and centrifuged (14,000 rpm, 10 min). Each sample (3 μL) was injected onto 
a 1.0 mm × 150 mm, 300 Å pore size, 3.5 μm particle size Symmetry 300 C18 column (Waters Corp., Milford, 
MA). The eluents were 95% water – 5% acetonitrile (eluent A) and 5% water – 95% acetonitrile (eluent B), both 
containing 0.1% formic acid. The flow rate was 20 μl/minute and the elution was performed at 25 °C. The mobile 
phase was: isocratic 50% B for 10 min followed by a linear gradient from 50% to 100% B in 20 min, maintained 
at 100% B for 10 min and, finally, a linear gradient to 50% B in 2 min. The re-equilibration time in 50% B was 
10 min. After HPLC separation, the eluent was sent to an Agilent 6210 TOF-MS equipped with an electrospray 
ion source. Negative full-scan mass spectra were recorded using Agilent Mass Hunter software in the mass range 
of m/z 100–1000. The following operational parameters were applied: capillary voltage: 3000 V; nebulizer pres-
sure: 20 psig; drying gas: 5 L/min; gas temperature: 300 °C; fragmentor voltage: 3500 V; skimmer voltage: 60 V; 
octapole RF: 250 V. The full scan data were processed using Agilent Mass Hunter Qualitative Analysis, ver. B.02.00 
software. The amount of compound 3 was measured from the extracted ion current (EIC) peak area (EIC m/z 
543.31 [M−H]−).
Molecular Docking simulations. Docking simulations were performed using Autodock v.4.2.2.51, using 
the crystallographic structure of a fragment of B-DNA complexed with cis-platin52 as target. The program stand-
ard default and a search grid encompassing the whole DNA fragment surface were used. The docking experiment 
consisted of 100 Lamarckian Genetic Algorithm runs. The generated docking poses were ranked in order of 
increasing docking energy values and clustered on the basis of a RMSD cut-off value of 2.0 Å. The structural anal-
ysis of the lowest energy solutions of each cluster, enabled us to identify the binding mode of 3. The structure was 
drawn using the program MarvinSketch [ChemAxon Ltd, Budapest, Hu]; The meso-acetamidophenyl chain of 3 
was handled as a flexible unit while the calix[4]pyrrole moiety was ‘frozen’ in the cone conformation that is nor-
mally adopted in calix[4]pyrrole-anion complexes. The double helix was treated as a rigid object. S.I. Fig. 2 was 
drawn using the program Chimera53. Additional docking simulations were conducted locking the calixpyrrole 
component of 3 in a 1,3-alternate conformation, as found when the calixpyrrole binds neutral guests. Despite the 
small differences in the pose of the macrocycles within the DNA minor groove, the acetyl moiety of 3 is posi-
tioned at a reasonable distance from the N3 atom of an adenine, allowing the possibility of forming a covalent 
bond to the double helix (S.I. Fig. 2C).
Data availability. Experimental data are available upon request to the corresponding authors.
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